Healthcare / Drug Manufacturers - Specialty & GenericCopenhagen
$1.09
+0.05 (+4.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-7.2M · quality 74.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$47M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-25.2%
↓Gross Margin
17.4%
↓Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.1%
FCF CAGR
—
FCF margin
-102.6%
FCF / Net income
3.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.0M · net income $-2.4M · FCF $-7.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.0M | $7.0M | $2.2M | $3.8M | $4.5M |
| Net Income | $-2.4M | $-2.4M | $-34.5M | $-17.6M | $-16.3M |
| EBITDA | $-1.7M | $-1.7M | $-24.2M | $-12.6M | $-13.3M |
| EPS | -0.06 | -0.06 | -1.79 | -0.70 | -0.70 |
| Gross Margin | 17.4% | 17.4% | 827.6% | -164.6% | -142.8% |
| Operating Margin | -25.3% | -25.3% | 172.8% | -424.3% | -368.1% |
| Net Margin | -34.0% | -34.0% | -1545.1% | -467.5% | -363.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | -1.14 | 0.37 | 0.45 |
| Current Ratio | 1.63 | 1.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.2M | $-7.2M | $-7.2M | $-10.2M | $-16.0M |
| Returns | |||||
| ROE | -25.2% | -25.2% | 992.8% | -68.0% | -67.5% |
| Valuation | |||||
| P/B | 4.58 | 4.58 | — | 2.43 | 8.69 |
| Growth & Yield | |||||
| Revenue Growth | 214.5% | 214.5% | -40.6% | -16.3% | — |
| EPS Growth | 96.6% | 96.6% | -154.3% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+165.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.79 → -0.06
Residual
+165.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.